Navigation Links
Quantros Director of Patient Safety and Risk Management is Elected Co-Chair of Patient Safety Work Group (PSWG) at HL7
Date:1/25/2009

Dr. Ali Rashidee will Serve a Two-Year Term as Co-Chair of the PSWG

SAN FRANCISCO, Jan. 26 /PRNewswire/ --

*NOTE TO EDITORS: Please note that this release was issued previously on January 22, 2009 containing factual errors which have been corrected herein.

Dr. Ali Rashidee MD, MS, the Director for Safety and Risk Management at Quantros, has been elected Co-Chair for the HL7 Patient Safety Work Group (PSWG). This international healthcare information organization's ongoing mission is to simplify the implementation of interfaces between health care applications for the exchange of key sets of clinical data minimizing the need for custom interface programming and program maintenance. The HL7 PSWG is the body tasked with developing the data interchange standard in the patient safety arena.

Dr. Rashidee has spent a large part of his career enhancing healthcare informatics for the betterment of healthcare safety and quality including tenure as a Co-Chair the HL7 PSWG from 2003-2005. In his current role at Quantros, Dr. Rashidee is responsible for ensuring Quantros Safety and Risk Management (SRM) solutions contain an extensive taxonomy and classification schema in alignment with national and international standards along with the business requirements for managing safety in various settings. More than 900 facilities throughout the United States use the SRM application daily to help reduce preventable medical errors and provide a safer environment of care. As a Co-Chair of the HL7 PSWG, Dr. Rashidee's knowledge and experience in patient safety will help further the group's data interoperability endeavors, both nationally and internationally.

"One of the key factors to improving patient safety is the ability for healthcare leadership to have right data presented across the systems to make clinically and fiscally sound decisions about environment of care and process improvement," according to Dr. Rashidee. "The HL7 PSWG is focused on defining data interchange standards for patient safety that breaks down data silos, facilitates interoperability and enables systems to provide a common language across healthcare technology solutions. I am honored to have been elected as a Co-Chair to help lead this very important endeavor."

"The work of the HL7 PSWG is a vital component for creating system interoperability in the area of patient safety," states Sanjaya Kumar, MD, President and CEO for Quantros. "Dr. Rashidee's experience in clinical informatics and patient safety taxonomy development and management with organizations such as AHRQ, PSO-PPC, NHSN, WHO and the FDA are a perfect complement to this team and its goals."

About Quantros

Quantros provides real-time solutions for safety and risk management, outcomes and performance monitoring, accreditation and compliance and surveillance and decision support for leading healthcare providers throughout the nation. Quantros' Web-based applications and value-added services provide a standard platform that creates actionable knowledge and guided direction to help clients save lives, improve quality and conserve assets. Through a variety of direct sales and vendor partners, more than 2,000 healthcare facilities use Quantros technology solutions every day.

Quantros team members include physicians, nurses and healthcare professionals as well as an experienced team of information technology engineers.

Quantros website: www.quantros.com

About HL7

Founded in 1987, Health Level Seven, Inc. (www.HL7.org) is a not-for-profit, ANSI accredited standards development organization dedicated to providing a comprehensive framework and related standards for the exchange, integration, sharing and retrieval of electronic health information that supports clinical practice and the management, delivery and evaluation of health services. HL7's more than 2,300 members represent approximately 500 corporate members, which include more than 90 percent of the information systems vendors serving healthcare.

HL7's endeavors are sponsored, in part, by the support of its benefactors: Accenture; Booz Allen Hamilton; Centers for Disease Control and Prevention; Duke Translational Medicine Institute (DTMI); Eclipsys Corporation; Eli Lilly & Company; Epic Systems Corporation; Food and Drug Administration; GE Healthcare Information Technologies; GlaxoSmithKline; IBM; Intel Corporation; InterSystems Corporation; Kaiser Permanente; Lockheed Martin; McKesson Provider Technologies; Microsoft Corporation; NHS Connecting for Health; NICTIZ National Healthcare; Novartis; Oracle Corporation; Partners HealthCare System, Inc.; Pfizer, Inc.; Philips Healthcare; QuadraMed Corporation; Quest Diagnostics Inc.; Sanofi-aventis R&D; Siemens Healthcare; St. Jude Medical; Sunquest Information Systems; Thomson Reuters; the U.S. Department of Defense, Military Health System; and the U.S. Department of Veterans Affairs.

Numerous HL7 Affiliates have been established around the globe including Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, India, Ireland, Italy, Japan, Korea, Mexico, The Netherlands, New Zealand, Singapore, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom and Uruguay.

HL7 Website: www.hl7.org


'/>"/>
SOURCE Quantros
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. US Pharmacopeia partners with Quantros to enhance the MEDMARX patient safety reporting program
2. Quantros Expanding Support for Alternative Web Browsers
3. Quantros Launches Patient Safety Organization Manager to Streamline PSO Data Management and Submission to the Network of Patient Safety Databases
4. Quantros Patient Safety Center Receives Certification as a Patient Safety Organization (PSO)
5. Quantros and ISMP Announce Collaboration Agreement to Further Medication Safety
6. Quantros and ISMP to Partner on PSO Initiatives
7. Quantros Director of Patient Safety and Risk Management is Elected Co-Chair of Patient Safety Special Interest Group (PSSIG) at HL7
8. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
9. HealthInsuranceFinders.com Launches Video Contest for Young Directors
10. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
11. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... ... February 22, 2017 , ... When it came ... contact center in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s grand ... recently invested $51 million to purchase and renovate the 185,000 square-foot office complex, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... The Waismann ... the thousands of individuals who have recently fallen victim to America’s opioid epidemic. Now, ... Orange County, California, where they are free from the shame, stigma, and harmful ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... to fewer trips the emergency room, fewer hospital admissions, and better blood pressure ... Managed Care® (AJMC®) finds. The study can be found here . , ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Prosthetic Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 9.2% over the next ... industry report analyzes the market estimates and forecasts for all the ...
(Date:2/23/2017)... 23, 2017 MabVax Therapeutics Holdings, ... development company, announces that it has received notice ... authorizing the initiation a Phase I clinical trial ... cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s ... to initiate the phase I clinical trial in ...
(Date:2/23/2017)... , Feb. 22, 2017 Orthopedic ... implant demand, as aging demographic patterns lead to ... Implants for sports- and exercise-related injuries, chronic back ... will lead sales gains. The future of medical ... addresses the following questions and more: - ...
Breaking Medicine Technology: